Achromatopsia – Epidemiology – Mature markets
Clarivate Epidemiology’s coverage of achromatopsia comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the diagnosed prevalence of achromatopsia for each country, as well as annualized case counts projected to the national population.
All patient populations are forecast over a period of 10 years.
Clarivate Epidemiology’s achromatopsia forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of achromatopsia over the forecast period?
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, Clarivate Epidemiology forecasts 4 achromatopsia patient populations, as follows:
- Diagnosed achromatopsia prevalent cases.
- Diagnosed achromatopsia prevalent cases with CNGA3+ mutation.
- Diagnosed achromatopsia prevalent cases with CNGB3+ mutation.
- Diagnosed achromatopsia prevalent cases with other/unknown mutations.
Note: coverage may vary by country.
